The
Food and Drug Administration approved the fast-acting erectile
dysfunction medication Stendra that was developed by Vivus Inc. (Nasdaq:
VVUS) and Auxilium Pharmaceuticals Inc. (Nasdaq: AUXL). Shares of Vivus climbed 65 cents to $4.53 while Auxilium stock eased 14 cents to $31.04.
FDA approves Vivus' ED treatment
September 18, 2014 at 13:15 PM EDT